Oscar Health, Inc. (OSCR) saw its stock plummet 8.35% in Sunday's trading session, following a bearish analyst report from Barclays. The significant drop comes after Barclays analyst Andrew Mok CFA reiterated a Sell rating on the health insurance company, maintaining a price target of $13.00.

The reaffirmation of the Sell rating by a major financial institution like Barclays appears to have sparked investor concern, leading to the sharp decline in Oscar Health's stock price. Analyst ratings and price targets often carry substantial weight in the market, influencing investor sentiment and trading decisions.

This development may signal ongoing challenges for Oscar Health in the competitive health insurance sector. Investors and market watchers will likely be closely monitoring the company's performance and any further analyst commentary in the coming days to gauge the potential long-term implications of this rating on Oscar Health's market position and stock valuation.